Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Axiogenesis Sign Co-Development and Marketing Agreement for Cell Lines

NEW YORK (GenomeWeb News) – Roche announced today that it will team up with Cologne, Germany-based Axiogenesis to develop and distribute Axiogenesis’ Cor.At cell line — specialized heart muscle cells that were derived from embryonic stem cells — in conjunction with the Roche xCELLigence platform.
 
Under the agreement, Roche Applied Sciences will market cell systems based on the Cor.At cell line that have been customized for the xCELLigence system, a platform designed to measure a range of parameters, including short-term cellular kinetics, cell proliferation, and toxicity. Cor.At cells represent physiologically normal embryonic stem cell-derived neonate or adult heart cells that are pure, easily stored, and quality controlled, said Roche in a statement.
 
Roche Applied Science Head Manfred Baier said that the combination of the xCELLigence platform and the Axiogenesis cells and technology is aimed at expanding Roche’s organ-specific cell analysis portfolio. “We are convinced that [the] Axiogenesis cell and technology portfolio will lead to products for cell-based assays to strengthen our new industrial standard for life science cell analysis in the future,” he said.
 
Axiogenesis was founded in 2000 and listed on the German stock market last December. The company has developed methods for using embryonic stem cells to generate tissues that can be used in drug development assays targeted at specific organs, focusing on cardiac, liver, endothelium, cartilage, and neuronal cells.
 
Financial terms of the agreement were not disclosed.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.